Articles

Blueprint Medicines’ avapritinib has been approved by FDA for the treatment of indolent systemic mastocytosis.

FDA Approves Blueprint Medicines’ Rare Blood Disorder Treatment

Ironwood Pharmaceuticals’ acquisition of VectivBio grants it the rights to apraglutide, a glucagon-like peptide being evaluated for gastrointestinal diseases.

Ironwood Inks $1 Billion Deal to Acquire VectivBio

The facility is based on a state-of-the-art design concept that allows maximum flexibility for a multi-product, multi-platform offering.

Aurigene Pharmaceutical Services Expands with New Facility 

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Alvotech and Advanz Pharma have signed a strategic partnership agreement for the supply and commercialization of five biosimilar candidates in Europe.

Partnership Forms to Commercialize Five Biosimilars in Europe

UK government supports AMR research with significant cash injection, provided through the Global AMR Innovation Fund (GAMRIF).

UK Government Boosts AMR Research with Cash Injection

ILC Therapeutics has entered into a strategic partnership with Dechra Pharmaceuticals to develop an atopic dermatitis treatment for dogs.

Scottish Biotech Forms R&D Partnership with Veterinary Medicine Group

Feliza Mirasol is the science editor for 

uBriGene Biosciences will acquire Mustang Bio’s Worcester, Mass., CGT manufacturing facility in a deal worth up to $11 million, expanding its operations into the US market.

uBriGene Expands into US Market with Acquisition of Mustang Bio's CGT Manufacturing Facility

With $73 million in financing from investment firms, Myeloid Therapeutics plans to accelerate its lead clinical candidate into Phase I/II development for treating solid tumors.

Myeloid Therapeutics Gets $73 Million to Advance mRNA-based Pipeline

The UK’s National Institute for Health and Care Excellence has recommended dapagliflozin (Forxiga) from AstraZeneca as a treatment option for adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction.

AstraZeneca’s Chronic Heart Failure Drug Gets Nod from NICE

ProBioGen’s Lenti.RiGHT is a lentivirus production platform for use in gene transfer applications.

News